Protection against chemotherapy induced damage in the digestive tract in childhood cancer patients

Completed

• Conditions: Chemotherapy induced damage in the digestive tract; Digestive System; Gastrointestinal toxicity

• Registration Number: ISRCTN13358395
• Lead Sponsor: Danone Research B.V. (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-27
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Children with acute non-lymphocytic leukaemia (ANLL), myelodysplastic syndromes (MDS), B-cell non-hodgkin's lymphoma (B-NHL), infant acute lymphoblastic leukaemia (ALL) who will receive two or more similar courses of chemotherapy
2. Children diagnosed with other malignancies who receive more than two similar courses of chemotherapy and develop mucosal barrier injury during one of the first courses
3. Aged 0 - 18 years
4. Informed consent

Exclusion Criteria

1. Clinical signs of inflammatory bowel disease, coeliac disease or cow's milk protein allergy
2. Radiotherapy of the abdomen less than 6 months before TGF-beta administration

Study & Design

• Study Type: Interventional
• Study Design: Not specified